When was PVP Biologics founded?

PVP Biologics was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is PVP Biologics located?

PVP Biologics is headquartered in San Diego, United States.

How many employees does PVP Biologics have?

As of May 31, 2026, the latest employee count at PVP Biologics is 1.

Is PVP Biologics a funded company?

PVP Biologics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Jan 05, 2017.

When was the latest funding round of PVP Biologics?

PVP Biologics' latest funding was a $***** Series B round on Jan 05, 2017, with participation from 1 investor.

Where does PVP Biologics rank among its competitors?

PVP Biologics ranks 249th amongst 405 active competitors, of which 143 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was DBV Technologies, which secured $307M in Apr, 2025.

Who are the top competitors of PVP Biologics?

PVP Biologics' top competitors include Biogen, Abcellera Biologics and argenx. Among them, DBV Technologies secured the most recent funding round in April, 2025.

PVP Biologics - 2026 Company Profile, Team, Funding & Competitors

Q: Is PVP Biologics an acquired company?

PVP Biologics got acquired by Takeda on Feb 26, 2020.

PVP Biologics is an acquired company based in San Diego (United States), founded in 2015 by Justin Siegel and David Baker. It operates as a Developing novel therapeutics to reduce the burden of living with celiac disease. PVP Biologics has raised $35M in funding. The company has 405 active competitors, including 143 funded and 112 that have exited. Its top competitors include companies like Biogen, Abcellera Biologics and argenx.

Company Details

Developing novel therapeutics to reduce the burden of living with celiac disease. The mission is to advance a product candidate designed to break down the immuno-reactive parts of gluten in the stomach, thereby avoiding painful symptoms and damage in the small intestine from accidental gluten ingestion. They are developing an oral enzyme for the treatment of celiac disease, in-licensed from the Institute for Protein Design at University of Washington. This innovative approach aims to provide a highly effective therapeutic product, addressing the challenges of maintaining a strict gluten-free diet and persistent symptoms reported by many patients. The company is focused on improving the lives of individuals affected by this disease through cutting-edge research and development in the field of gastroenterology and immunology.

Website: www.pvpbio.com/
Social

Key Metrics

Founded Year

2015

Location

San Diego, United States

Stage

Acquired

Total Funding

$35M in 1 round

Latest Funding Round

Series B, Jan 05, 2017, $*****

Investors

Takeda & 1 more

Ranked

249^th among 405 active competitors

Employee Count

1 as on May 31, 2026

Similar Companies

Biogen & 474 more

Exit Details

Acquired by Takeda (Feb 26, 2020)

View PVP Biologics' full profile

PVP Biologics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PVP BIOLOGICS, INC. CIN: 5842805 , United States, Active		-	9 (As on Dec 31, 2017)	-
PVP BIOLOGICS, INC. CIN: 461206176 , United States, Active	Dec 31, 1999	-	7 (As on Dec 31, 2019)	-

PVP Biologics got acquired by Takeda on Feb 26, 2020 at an acquisition amount of $*****.

Click here to take a look at PVP Biologics's acquisition in detail

PVP Biologics has raised a total funding of $35M over 1 round. Its latest funding round was a Series B round on Jan 05, 2017 for $*****. 1 investor participated in its latest round. PVP Biologics has 2 institutional investors.

Here is the list of recent funding rounds of PVP Biologics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 05, 2017	2633642	Series B	1687844	5619480	8390636	6219863

Access funding benchmarks and valuations. Sign up today!

View details of PVP Biologics's funding rounds and investors

The founders of PVP Biologics are Justin Siegel and David Baker.

Here are the details of PVP Biologics' key team members:

Justin Siegel: Co-Founder of PVP Biologics.
David Baker: Co-Founder of PVP Biologics.

View details of PVP Biologics's Founder profiles and Board Members

PVP Biologics' employee count trend

PVP Biologics has 1 employees as of May 26. Here is PVP Biologics's employee count trend over the years:

Uncover PVP Biologics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PVP Biologics include Biogen, Abcellera Biologics and argenx. Here is the list of Top 10 competitors of PVP Biologics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Gershon Capital & 10 others	78/100
2nd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
4th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
5th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	BlackRock, Woodford Investment Management ... & 50 others	69/100
6th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, SR One & 20 others	69/100
7th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100
8th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Apax & 16 others	68/100
9th	Theravance Biopharma 2001, Francisco (United States), Public	Developer of therapeutics for inflammatory and immunological diseases	-	Sierra Ventures, Acorn Bioventures & 6 others	67/100
10th	Apellis Pharmaceuticals 2008, Crestwood (United States), Acquired	Developer of therapeutics for the treatment of rare diseases	$213M	Sectoral, Hillhouse & 21 others	67/100
249th	PVP Biologics 2015, San Diego (United States), Acquired	Developing novel therapeutics to reduce the burden of living with celiac disease	$35M	Takeda, Sahsen Ventures	31/100